Klimek, Ludger
Bergmann, Karl-Christian
Brehler, Randolf
Pfützner, Wolfgang
Zuberbier, Torsten
Hartmann, Karin
Jakob, Thilo
Novak, Natalija
Ring, Johannes
Merk, Hans
Hamelmann, Eckard
Ankermann, Tobias
Schmidt, Sebastian
Untersmayr, Eva
Hötzenecker, Wolfram
Jensen-Jarolim, Erika
Brockow, Knut
Mahler, Vera
Worm, Margitta
Funding for this research was provided by:
Charité
Article History
Received: 21 January 2021
Accepted: 25 January 2021
First Online: 19 April 2021
Conflict of interest
: L. Klimek reports grants and/or personal fees from Allergopharma, MEDA/Mylan, HAL Allergie, ALK Abelló, LETI Pharma, Stallergenes, Quintiles, Sanofi, ASIT Biotech, Lofarma, Allergy Therapeutics, AstraZeneca, GSK, Inmunotek, Cassella med and Novartis, outside of the submitted work; and memberships in the following organizations: AeDA, DGHNO, German Academy for Allergology and Clinical Immunology, ENT-BV, GPA, EAACI. L. Klimek is editor in chief of <i>Allergo Journal International</i>. R. Brehler reports fees and/or research support from ALK, Allergopharma, Bencard, HAL, Leti, Stallergenes, Astra Zeneca, GSK, MedUpdate, Novartis, BiotechTools, Genentech and Circassia, outside of the submitted work. W. Pfützner reports grants and/or personal fees and/or non-financial support from ALK-Abello, Biomay, Cilag-Janssen, Lilly, Novartis and Thermo Fisher outside of the submitted work. T. Zuberbier reports grants and/or personal fees from AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, FAES, HAL, Leti, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB, Henkel, Kryolan and L’Oréal outside of the submitted work; and the following organizational affiliations: Member of the committee: WHO initiative “Allergic Rhinitis and its Effects on Asthma” (ARIA), Board member: German Society for Allergy and Clinical Immunology (DGAKI), Chairman of the Board: Foundation of the European Center for Allergy Research (ECARF), President: Global European Network on Allergy and Asthma (GA2LEN), Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). K. Hartmann has received research grants outside of the present work from Euroimmun and Thermofisher as well as consulting or lecture fees from Allergopharma, ALK-Abelló, Blueprint, Deciphera, Menarini, Novartis and Takeda. T. Jakob reports grants and/or personal fees and/or non-financial support from Novartis, ALK-Abello, Allergy Therapeutics/Bencard, Allergopharma, and Thermo Fisher outside of the submitted work. T. Jakob is editor in chief of <i>Allergo Journal International</i>. N. Novak reports grants and/or personal fees from Alk Abelló, HAL Allergy, Stallergenes Geer, Leti Pharma, Novartis, Leo Pharma, Abbvie, Sanofi Genzmye, Lofarma and Bencard Allergy Therapeutics, outside of the submitted work. J. Ring reports fees from Mylan and Allergika outside of the submitted work. T. Ankermann received fees outside the submitted work from the following companies and organizations: Abbvie, Allergopharma, Chiesi, Infectopharm, Novartis, UKSH Akademie, RG, Springer Verlag, Wissenschaftliche Verlagsgesellschaft, GPP eV, GPA eV, nappa eV and ÖGKJ eV and is an advisory agent active for Boehringer Ingelheim, Aimmune and Allergopharma. S. Schmidt reports grants and/or personal fees and/or non-financial support from Allergopharma, ALK, Bencard, Gilead, Mundipharma, Novartis, Vertex, HAL, Sanofi, Olympus, Infectopharm, Pari and Pfizer outside of the submitted work. V. Mahler The positions stated in this work represent the personal views of the author as an expert in the field of allergology and must not be understood or cited as the view of the Federal Institute for Vaccines and Biomedical Medicines, the European Medicines Agency or one of its Committees or working groups. There are no conflicts of interest. M. Worm reports fees for consulting and lecture activities from Regeneron Pharmaceuticals, DBV Technologies SA, Stallergenes GmbH, HAL Allergie GmbH, Bencard Allergie GmbH, Allergopharma GmbH & Co. KG, ALK-Abelló Arzneimittel GmbH, Mylan Germany GmbH, Leo Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Aimmune Therapeutics UK Limited, Actelion Pharmaceuticals Deutschland GmbH, Novartis AG, Biotest AG, AbbVie Deutschland GmbH & Co. KG and Lilly Deutschland GmbH, outside of the submitted work. K.-C. Bergmann, H. Merk, E. Hamelmann, E. Untersmayr, W. Hötzenecker, E. Jensen-Jarolim and K. Brockow declare that they have no competing interests.